RE:Here's why I think we should wait for--- These were the headings of the ann of the 18th of April 2018:
Patient Five Shows No Clinical Evidence or Presence of NMIBC at 90 Day Cystoscopy Analysis
Patient Six Shows No Clinical Evidence or Presence of NMIBC to Date
These words ‘No Clinical Evidence or Presence of NMIBC’ were only ever used for Patients Five and Six so if we see them used again we can draw our own conclusions. Patient 6 was treated only 67 days`before this announcement was made. These initial analyses remained unaltered at 18 months.
In his lecture in Paris on the 12th of November 2019 Dr.Lilge stated that:
‘Theralase is continuously improving the quality of PDT treatment with TLD-1433 and the optimized TLC-3200 laser system.’
He would not have been able to say this if the initial Phase II readings had been any worse than those taken for Patients 5 and 6 in Phase IB.
Again we can draw our own conclusions. Wonder if many of the Triallists will need that second treatment at 180 days and whether Investment Analysts will ever pay attention to any of this?